Consequently, the identification of biomarkers, specifically microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden (TMB), and Epstein-Barr virus (EBV), has become increasingly crucial in guiding systemic therapy strategies [4]. Here, CD274 is linked to neoplasm.